Abstracts tagged "Skin Eruptions"

Abstract Number: 210 • 2016 ACR/ARHP Annual Meeting
Skin Events with Febuxostat in Gout Patients and Previous Skin Reactions to Allopurinol. a Retrospective Review
Neus Quilis¹, Mariano Andrés^1,2, Carlos Muñoz³, Paloma Vela^1,2 and Eliseo Pascual⁴, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ³Sección de Inmunología, Hospital General Universitario de Alicante, Alicante, Spain, ⁴Departamento de Medicina Clínica, Emeritus Professor, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Allopurinol is the most used urate-lowering agent for patients with gout, but around 10% of patients show intolerance to this drug, often at skin,…
Abstract Number: 170 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases
Jasvinder A. Singh¹, Shuo Yang² and Jeff Foster³, ¹University of Alabama and VA Medical Center, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Dermatologic side effects to use of gout treatments are concerning to patients. The goal of the study was to assess the risk of occurrence…
Abstract Number: 163 • 2014 ACR/ARHP Annual Meeting
Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat
Thomas Bardin¹, Gérard Chales², Tristan Pascart³, René-Marc Flipo⁴, Jean-Claude Roujeau⁵, Aurélie Delayen⁶ and Pierre Clerson⁷, ¹Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, ²Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, ³Rheumatology, Saint-Philibert Hospital, LOMME, France, ⁴rheumatology, Rene Salengro hospital, Lille, France, ⁵Dermatology, University Paris Est, Créteil, France, ⁶Orgamétrie biostatistiques, Roubaix, France, ⁷Orgametrie, Roubaix, France
Background/Purpose: Allopurinol can lead to skin toxicity. Minor skin reactions are reported in 2-4% of patients and life threatening severe cutaneous reactions (SCARs) in 0.1-0.4%.…
Abstract Number: 2750 • 2013 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety Of IL1 Receptor Antagonist In Schnitzler’s Syndrome : A French Multicenter Study
Antoine Néel¹, Agathe Masseau¹, Sebastien Barbarot², Benoit Henry³, Pierre-Jean Weiller⁴, Olivier Decaux⁵, Xavier Kyndt⁶, Xavier Puechal⁷, Arnaud Hot⁸, Pierre Pottier¹, Amar Smail⁹, David Launay¹⁰, Jean-Marie Berthelot¹¹, Eric Hachulla¹², Leonardo Astudillo¹³, Pierre-Yves Hatron¹², Laurent Sailler¹³, Aurelien Lorleac'h¹⁴, Achille Aouba¹⁵, Bérangère Cador¹⁶, Renato Fior¹⁷, Robin Dhote¹⁸, Fabrice Bonnet¹⁹, Jean-Dominique de Korwin²⁰ and Mohamed Hamidou¹, ¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²Dermatology, Nantes University Hospital, Nantes, France, ³Infectious and Tropical Diseases, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Internal Medicine Department, La Timone University Hospital, Marseille, France, ⁵Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁶Department of Nephrology and Internal Medicine, CH, Valenciennes, Valenciennes, France, ⁷Internal Medicine, Hôpital Cochin, Paris, France, ⁸Internal Medicine, Edouard Herriot University Hospital, Lyon, France, ⁹Internal Medicine Department, CHU Amiens Nord, Amiens, France, ¹⁰Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹¹Rheumatology Unit, Nantes University Hospital, Nantes, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ¹⁴Internal Medicine Department, Lorient Hospital, Lorient, France, ¹⁵Hematology, Necker University Hospital, Paris, France, ¹⁶Internal Medicine Department, Rennes University Hospital, Rennes, France, ¹⁷Internal Medicine Department, Antoine Béclère University Hospital, Clamart, France, ¹⁸Internal Medicine, Avicenne University Hospital, Bobigny, France, ¹⁹Internal Medicine, Bordeaux University Hospital, Bordeaux, France, ²⁰Internal Medicine Department, Nancy University Hospital, Nancy, France
Background/Purpose: Schnitzler's syndrome is a rare late onset auto-inflammatory disease which associates a chronic/recurrent urticarial skin rash, a monoclonal gammopathy (mostly IgM kappa), and a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].